Net loss of $72 million, or $0.48 per share Read more…
Net loss was $154.9 M, or $1.04 per share … Read more…
Every controversial story has many detractors and few supporters Read more…
Net loss in Q2/12 was $96.1M or $0.65 per share Read more…
Report Card … so far Read more…
Net loss was $103.9M or $0.70 per share Read more…
Q4/11 net loss was $38.09M or $0.26 per share Read more…
Board of Directors has elected John H. Johnson to the position of President and CEO, Read more…
The unexpected rise in Provenge’s cost of goods and sales of the prostate cancer therapy Read more…
1st Patient Enrolled in HER2+ bladder carcinoma study; the 2nd Active Cellular Immunotherapy Product Candidate, DN24-02
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.